by BioGenex | Aug 16, 2023 | Blog
Introduction: In the realm of immunohistochemistry (IHC), achieving accurate and reliable results is paramount for researchers and clinicians alike. Antigen retrieval, a critical step in the IHC process, plays a pivotal role in unmasking antigens and optimizing...
by BioGenex | Jul 30, 2023 | Blog
Introduction: Malignant melanoma, poses a significant health concern globally as it has a high mortality. Although it’s the most serious form of skin cancer, it is curable if diagnosed ahead of time. So, an early and accurate diagnosis plays a crucial role in...
by BioGenex | Jun 23, 2023 | Blog
Introduction: Lung inflammation, also known as pneumonitis, is a condition characterized by the inflammation of lung tissue. It can be caused by various factors, including infections, exposure to irritants, autoimmune disorders, and genetic abnormalities. In recent...
by BioGenex | Jun 14, 2023 | Blog
Introduction: Melanoma Symptoms, Treatment, and the Role of PRAME in Accurate Melanoma Diagnosis Melanoma, a type of skin cancer, can be challenging to diagnose accurately. Recognizing melanoma symptoms, such as the appearance of new moles or changes in existing...
by BioGenex | Dec 17, 2021 | News
March is National Colorectal Cancer Awareness Month. The 5-year survival rate for a colorectal cancer patient when detected at an early stage is 90%, which drastically plummets down to 14% if cancer gets spread to a distant part of the body. Only 39% of patients are...
by BioGenex | Dec 17, 2021 | News
BioGenex worked with Fremont city officials to ensure the supply of raw materials that were key to Roche’s Covid-19 diagnostic. The call came on a Monday in mid-March: A Covid-19 test by BioGenex Laboratories’ big customer, Roche Molecular Solutions, had...
by BioGenex | Dec 17, 2021 | News
BioGenex, a pioneer in automated staining solution provider for cancer diagnostics announces the launch of three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis. The new launch includes: CD8A: Studies have confirmed that CD8 expression is a...
by BioGenex | Dec 16, 2021 | Blog
We are pleased to bring you the BioGenex NanoVIP a fully automated bench-top integrated system with visualization kits for fluorescence in situ hybridization (FISH), in situ hybridization (ISH), miRNA ISH, and immunohistochemistry (IHC). The compact 10-slide design...
by BioGenex | Dec 16, 2021 | Blog
Summary: MicroRNAs (miRNA) are approximately 19–24 nucleotides in length and base-pair to complementary sites within messenger RNA (mRNA). Aided by the “RISC” complex this binding functions to promote down-regulation of the mRNA’s protein product. MicroRNAs are an...
by BioGenex | Dec 16, 2021 | Blog
Summary: World-wide approximately 5% of all cancers are determined to have an occult or unknown primary location, upon initial assessment, prior to completing a full pathology report. [Oien] Unfortunately in 20-50% of CUP cases the primary tumor is never found. These...
by BioGenex | Nov 9, 2021 | Biomarker
Renal Cell Carcinoma (RCC) Classification – ccRCC, pRCC, and chRCC using New miRNA Biomarker Pane Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Renal cell carcinoma (RCC) consists of an array of morphologically and genetically distinct...
by BioGenex | Nov 9, 2021 | Biomarker
Prostate Cancer (PC) and Benign Prostatic Hyperplasia (BPH) Differentiation by New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Prostate cancer and benign prostatic hyperplasia (BPH) are the most frequent and deadly...
by BioGenex | Nov 9, 2021 | Biomarker
Triple Negative Breast Cancer – Differentiation of TNBC (ER-, PR-, and HER2/neu-) using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Like many cancers, breast cancers are highly diverse with a range of distinct...
by BioGenex | Nov 9, 2021 | Biomarker
Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AD) Differentiation in Non-Small Cell Lung Cancer (NSCLC) using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Lung cancer represents a heterogeneous group of tumors...
by BioGenex | Nov 9, 2021 | Biomarker
Wild Type and Mutated BRCA – Differentiation of Breast Cancer using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Breast cancer represents a heterogeneous group of tumors characterized by a wide range of clinical,...
by BioGenex | Nov 9, 2021 | Biomarker
Biomarker Panel for Differentiation of Wild Type and Breast Cancer Susceptibility Gene (BRCA) Mutated Breast Cancer miRNA SSNA in situ Hybridization System Breast cancer represents a heterogeneous group of tumors characterized by a wide range of clinical, pathologic...
by BioGenex | Nov 9, 2021 | Biomarker
Glioma Prognostic Subtyping – Astrocytoma, Oligodendroglioma, Meningioma, and Glioblastoma using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Malignant gliomas are extremely aggressive and lethal form of brain...
by BioGenex | Nov 9, 2021 | Biomarker
Squamous Cell Carcinoma Differentiation of Cervical Cancer using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Cervical cancer is one of the most common malignant tumors of the female reproductive tract. It is the...
by BioGenex | Nov 8, 2021 | Biomarker
Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma Differentiation by New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CC) are two highly aggressive...
